Abbott, a global healthcare company, announced plans to separate its Nutrition business into an independent, publicly traded company with approximately $8.5 billion in annual sales. The proposed transaction will establish a standalone nutrition company while allowing Abbott to concentrate on its higher-growth medical devices, diagnostics, biowearables, and established pharmaceutical businesses.
